Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.1584 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Bilal Tariq und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Pharmacometrics, BeOne Medicines Ltd, San Carlos, CA, USA. Hauptthemen laut MEDLINE: Food-Drug Interactions, Pyrimidines, Pyrazoles, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Zanubrutinib is a next‐generation Bruton tyrosine kinase inhibitor approved for treating B‐cell malignancies. Two phase 1 studies evaluated a new 160‐mg zanubrutinib tablet versus 80‐mg capsules. In study BGB‐3111‐115 (n = 43), a randomized 3‐period crossover trial, relative bioavailability and food effects were assessed. Under fasted conditions, systemic exposure (area under the concentration‐time curve [AUC]) was comparable between tablets and capsules at both 160‐ and 320‐mg doses. A high‐fat meal increased tablet maximum plasma concentration (C max ) by 47%‐79% but had minimal effect on AUC (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology & Pharmacometrics, BeOne Medicines Ltd, San Carlos, CA, USA.
- Biostatistics, BeOne Medicines Ltd, San Carlos, CA, USA.
- Chemistry Analytical Research & Development, BeOne Medicines Ltd, Suzhou, China.
Zitieren
APA
Tariq, B., Lin, C., Mundra, V., Gao, Y., Zhang, D., & Ou, Y. C. (2026). Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1584
Vancouver
Tariq B, Lin C, Mundra V, Gao Y, Zhang D, Ou YC. Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.1584
BibTeX
@article{Tariq2026,
author = {Tariq, Bilal and Lin, Chester and Mundra, Vaibhav and Gao, Yang and Zhang, Dan and Ou, Ying C},
title = {Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.1584}
}
EUVIMED